Empowering New Zealand Nurses for Excellence in Healthcare
Bicultural Structure
Membership includes belonging to a bicultural organisation focused on professional nursing issues and community health.
Insurance Coverage
Members receive up to $1 million indemnity insurance in New Zealand (not applicable for retired members). (Conditions apply).
Access to Publications
Members have access to the ‘Nursing Praxis in Aotearoa New Zealand’ journal.
Influence and Networking
Members contribute to a significant influencer in health policy decision-making and join a dynamic network of professional nurses committed to high standards of practice.
9 April 2026
Nurse Practitioner Rural Health
Hāwera Hospital Permanent, part-time or full-time role Play a pivotal role in rural health Health New Zealand | Te Whatu Ora is firmly grounded in the principles of Te Tiriti o Waitangi and is committed to building a health system that serves all New Zealanders. About the role Mātanga tapuhi nurse practitioners have advanced education, clinical training and the demonstrated competence and legal authority to practise beyond the level of a registered nurse. In this role, you will: work...
9 April 2026
Discontinuation: Univent nebules. New listing: Ipratropium Viatris brand
We are writing to inform you of the following: Discontinuation: Ipratropium bromide nebuliser soln, 250 mcg per ml, 2 ml ampoule (Univent) New listing: Ipratropium bromide nebuliser soln, 0.5mg per 2ml ampoule (Viatris) Ipratropium bromide nebuliser soln, 250 mcg per ml, 2 ml ampoule (Univent) has been discontinued. Remaining Univent stock is being reserved for ambulances. The alternate Section 29 Accord brand currently listed is expected to be depleted by May 2026. A second alternate,...
9 April 2026
Decision to fund two new combination treatments and widen access to another for people with a type of blood cancer
Pharmac has decided to fund two new combination treatments and widen access to ibrutinib for people with chronic lymphocytic leukaemia (CLL) from 1 May 2026.Under this decision: People with CLL will be able to receive venetoclax with ibrutinib or venetoclax with obinutuzumab as first‑line treatments, meaning they can be used as an initial treatment option rather than after other treatments have been tried. Access to ibrutinib will be widened so it can be used on its own as a second line...
9 April 2026
Mental Health and Addiction update – April 2026
I hope you were all able to take a moment to rest and recharge over the long weekend. The start of the year has been a busy one, and I want to acknowledge the work you do every day to support people, families, whānau and communities, and the impact it can have on your own wellbeing. Today marks an important milestone. We have launched public consultation on the draft Mental Health and Wellbeing Strategy – a ten-year plan to guide our collective efforts to improve mental health and wellbeing...
9 April 2026
Decision to fund letermovir to prevent serious infection
Pharmac has decided to fund letermovir, a medicine that helps prevent serious viral infection in people with very weak immune systems. From 1 May 2026, letermovir will be funded for people who have had a stem cell transplant, as well as a small number of other people with severe immunosuppression who cannot use other funded antiviral medicines. This decision follows public consultation and strong feedback from clinicians involved in stem cell transplant care, patient groups, and Pharmac’s...
9 April 2026
Continuing Professional Development
Our latest webinars and podcast for you: Whole of life protection: A focus on adult vaccination WEBINAR 14 April: Nikki Turner on the importance of adult immunisation as part of comprehensive preventive care in primary practice. Register here Redefining insomnia management WEBINAR 21 April: David Cunnington, a specialist sleep physician, will review contemporary insomnia management, including CBT-I, and discuss the role of medications, including lemborexant, a newer agent. Register here...
8 April 2026
Have your say: Pharmac consultation on potential medicine brand changes
Pharmac is now consulting publicly on potential brand changes for medicines included in the 2025/26 annual tender. Consultation on possible brand changes through the annual tender This year, around a third of the over 400 items that were tendered may result in a brand change. We want to ensure that any decisions we make are informed by the experiences and needs of prescribers and the people they care for. Consultation opens on Wednesday 8 April and closes on Monday 4 May. More information...
8 April 2026
Ministry of Health - Health Improvement & Innovation Digest
Issue 339 - 2 April 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here . You can also access other recent issues of the digest here. If you have any queries, please email us at library@health.govt.nz If you have any queries, please email us at ...
7 April 2026
Decision to widen access to nivolumab and ipilimumab for resectable melanoma
We are pleased to announce our decision to widen access to nivolumab and ipilimumab for treatment of resectable melanoma. From 1 May 2026 , nivolumab in combination with ipilimumab will be funded for people with stage 3B to stage 4 melanoma that can be removed with surgery. This decision was informed by consultation feedback from people with melanoma, their whānau, advocacy groups, clinicians and other health sector stakeholders. You can read the full decision here: Decision to widen access...
31 March 2026
Prompt diagnosis of AF using a smartwatch
This RCT 1 enrolled 437 secondary care patients aged ≥65 years (mean 75) with CHA₂DS₂-VASc scores ≥2 in men and ≥3 in women. Participants were assigned to 6-month (180-day) monitoring, using an Apple smartwatch with photoplethysmography and single-lead ECG functions, or to standard care. Over 6 months, atrial fibrillation (AF) was detected in 21 patients (9.6%) in the intervention group versus 5 (2.3%) in controls. Several asymptomatic AF episodes were identified only in the intervention...
31 March 2026
Nurse Practitioner
Nurse Practitioner Permanent full-time 0.9-1.0 FTE | Salary $142,470-$157,252 depending on experience The Gardens, Manurewa location, with free parking on site Onsite café with discounted coffee, health insurance, boutique 2 nd edition store and more… At Tōtara Hospice, you’re not just a nurse — you’re a purpose-driven clinician making a real impact every day. Imagine starting your morning surrounded by native trees, peaceful gardens, and a calm oasis far from the city rush — maybe with a...
30 March 2026
Pharmac Update: Primary Care Prescribers | 27 March 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 27 March 2026. It includes information on: New updates Resolved Supply Issues Supply issue: Dexamfetamine 5 mg tablets There is a supply issue affecting the Noumed brand of dexamfetamine 5 mg tablets. The supplier has advised that stock will be unavailable from April to June 2026. From 1 April, the Aspen brand of dexamfetamine 5 mg tablets will be listed in the...
30 March 2026
Tender results
Kia ora, Please follow this link to our website for the March 2026 Tender Notification. Ngā mihi, Stefanie Moir | Tender Analyst Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 | www.pharmac.govt.nz
30 March 2026
Nurse Practitioner - Christchurch Opportunity
Triple0 is currently working with a modern, newly established practice in Christchurch that's continuing to grow, and they're looking for a Nurse Practitioner to join their supportive, forward-thinking team. While a permanent role is preferred, there's also flexibility with a 6–12 month option—ideal if you're considering relocating or keen to experience a new environment before committing longer term. ✨ What's on offer: Competitive rates Positive, collaborative team culture Integrated...
29 March 2026
Goodfellow Unit
Enhance your Dermatology Expertise: Join Our Online Session on Saturday, 16 May. Skin conditions are among the most frequent presentations in primary care. This 4-hour webinar brings together top New Zealand dermatology specialists to help you navigate these complexities with confidence. What to expect: Expert-led, primary care–focused updates on recognising and managing common dermatology presentations seen in everyday practice. Practical guidance on diagnosing and treating conditions across...
29 March 2026
Pharmac - Supply Update
Conflict in the Middle East Suppliers are working closely with Pharmac to reduce any disruption to people in New Zealand. Where issues arise, we will communicate them on our website and through this email. Conflict in the Middle East: Impact on the supply chain New medicine supply notices Ensure: Pack size change Ensure powders are changing from 850 g to 800 g. The price remains the same. New Pharmacodes are listed from 1 April. New packs will start arriving during June 2026. Fluconazole...
27 March 2026
Proctosedyl suppository. New alternative listed: Scheriproct suppository
We are writing to inform you of - Supply issue: Proctosedyl suppository. New alternative listed: Scheriproct suppository. Key messages: The supplier (AFT) has informed Pharmac that due to a delayed shipment that Proctosedyl suppositories are out of stock. Scheriproct suppositories have been listed (funded) on the Pharmaceutical Schedule. Scheriproct suppositories will be available in New Zealand by early April. Ultraproct suppositories have been out of stock for a long period. Pharmac has...
26 March 2026
Proposal to award Principal Supply Status for permanent coronary drug-eluting stents to Medtronic
Kia ora This link will take you to the proposal to award Principal Supply Status for permanent coronary drug-eluting stents to Medtronic New Zealand Limited. A list of products included in the proposal is attached . Pharmac welcomes feedback on this proposal. To provide feedback, please submit it in writing by 4pm Tuesday 28 April 2026 to Sam.Edlund@Pharmac.govt.nz Ngā mihi, Sam Edlund | Procurement Manager _______________________________________________________________ Pharmac | Te...
24 March 2026
Continuing Professional Development
Our latest webinars and podcasts for you: Whole of life protection: A focus on adult vaccination WEBINAR 14 April: Nikki Turner on the importance of adult immunisation as part of comprehensive preventive care in primary practice. Register here Redefining insomnia management WEBINAR 21 April: David Cunnington, a specialist sleep physician, will review contemporary insomnia management, including CBT-I, and discuss the role of medications, including lemborexant, a newer agent. Register here...
Areas of interest
